Claims for Patent: 9,963,511

Summary for Patent: 9,963,511

Title:	Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
Abstract:	Herein is reported an expression vector comprising--an antibody light chain expression cassette, --an antibody heavy chain expression cassette, and--a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5\' to 3\' sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.
Inventor(s):	Huelsmann; Peter Michael (Habach, DE), Knoetgen; Hendrik (Penzberg, DE)
Assignee:	HOFFMANN-LA ROCHE INC. (Little Falls, NJ)
Application Number:	14/367,043
Patent Claims:	1. A method for transfection of a eukaryotic cell with an expression vector encoding an antibody for the production of the antibody comprising the following steps: a) providing the expression vector, wherein the vector comprises (i) a prokaryotic plasmid propagation unit comprising an origin of replication and a prokaryotic selectable marker, (ii) one or more expression cassettes encoding an antibody light chain and an antibody heavy chain, and (iii) an expression cassette encoding a eukaryotic selection marker; b) linearizing the vector of a) and removing the prokaryotic propagation unit from the vector of a); c) transfecting the eukaryotic cell with the vector of b); and d) producing the antibody. 2. The method according to claim 1, wherein the expression vector comprises: a) the antibody light chain expression cassette; b) the antibody heavy chain expression cassette; and d) the selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5' to 3' sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. 3. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other a promoter selected from the human elongation factor 1 alpha promoter, the human CMV promoter, and the SV40 promoter. 4. The method according to claim 2, wherein one, two, or all three expression cassettes of a), b), or c), comprise the human elongation factor 1 alpha promoter. 5. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other the human elongation factor 1 alpha promoter. 6. The method according to claim 2, wherein the expression cassettes do not comprise a terminator sequence. 7. The method according to claim 2, wherein one, two, or all three expression cassettes of a), b), or c) comprise the human CMV promoter. 8. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other the human CMV promoter. 9. The method according to claim 2, wherein one, two, or all three expression cassettes comprise the bovine growth hormone polyA signal sequence. 10. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other the bovine growth hormone polyA signal sequence. 11. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other a polyA signal sequence selected from the bovine growth hormone polyA signal sequence and the SV40 polyA signal sequence. 12. The method according to claim 2, wherein one, two, or all three expression cassettes comprise the human gastrin terminator sequence after the polyA signal sequence. 13. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other the human gastrin terminator sequence after a polyA signal sequence. 14. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette and/or the selection marker expression cassette comprise independently of each other 5' to 3' direction the bovine growth hormone polyA signal sequence and the human gastrin terminator sequence. 15. The method according to claim 2, wherein the promoter of one, two, or all three expression cassettes comprises an Intron A. 16. The method according to claim 2, wherein one, two, or all three expression cassettes comprise the SV40 polyA signal sequence. 17. The method according to claim 16, wherein one, two, or all three expression cassettes comprise the SV40 promoter. 18. The method according to claim 2, wherein the antibody light chain expression cassette and/or the antibody heavy chain expression cassette comprises at least one intron. 19. The method according to claim 2, wherein the nucleic acid encoding the antibody light chain expression cassette and/or the antibody heavy chain expression cassette comprises cDNA. 20. The method according to claim 2, wherein the expression vector is encoding a bispecific antibody. 21. The method according to claim 20, wherein the bispecific antibody has a first binding specificity or binding site that specifically binds to a first antigen or a first epitope on a first antigen and the bispecific antibody has a second binding specificity or binding site that specifically binds to a second antigen or second epitope on a second antigen. 22. The method according to claim 2, wherein the expression vector comprises: a) a first expression cassette comprising in 5' to 3' direction a promoter, a nucleic acid encoding a first antibody heavy chain, a polyA signal sequence, and optionally a terminator sequence; b) a second expression cassette comprising in 5' to 3' direction a promoter, a nucleic acid encoding a first antibody light chain, a polyA signal sequence, and optionally a terminator sequence; c) a third expression cassette comprising in 5' to 3' direction a promoter, a nucleic acid encoding a second antibody heavy chain, a polyA signal sequence, and optionally a terminator sequence; and d) a fourth expression cassette comprising in 5' to 3' direction a promoter, a nucleic acid encoding a second antibody light chain, a polyA signal sequence, and optionally a terminator sequence. 23. The method according to claim 2, wherein the expression vector comprises: a) a first expression cassette comprising in 5' to 3' direction a promoter, a nucleic acid encoding a first antibody heavy chain, a polyA signal sequence, and optionally a terminator sequence; and b) a second expression cassette comprising in 5' to 3' direction a promoter, a nucleic acid encoding a second antibody heavy chain, a polyA signal sequence, and optionally a terminator sequence, wherein the antibody light chain is a common light chain for both antibody heavy chains. 24. The method according to claim 2, wherein the expression vector further comprises a second antibody heavy chain expression cassette, wherein at least one of the antibody heavy chain expression cassettes and the antibody light chain expression cassette and the selection marker expression cassette are arranged unidirectional; and wherein the unidirectional expression cassettes are arranged in the 5' and 3' sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. 25. The method according to claim 21, wherein one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising a hole mutation. 26. The method according to claim 21, wherein one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising a knob mutation. 27. The method according to claim 20, wherein one of the antibody light chain expression cassettes encodes an antibody light chain variant comprising an antibody light chain variable domain and an antibody heavy chain CHI domain as constant domain and/or one of the antibody light chain expression cassettes encodes an antibody light chain comprising an antibody light chain variable domain and an antibody light chain CL domain as constant domain. 28. The method according to claim 20, wherein one of the antibody heavy chain expression cassettes encodes an antibody heavy chain variant comprising as first constant domain an antibody light chain constant domain (CL), and/or one of the antibody heavy chain expression cassettes encodes an antibody heavy chain comprising as first constant domain an antibody heavy chain CHI domain.

Details for Patent 9,963,511

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2031-12-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2031-12-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2031-12-22